

- Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9–29.
- Ehrlich CA, Young PCM, Cleary RE. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometrial: therapeutic implications. *Am J Obstet Gynecol* 1981;141:539–546.
- McPherson CP, Sellers TA, Potter JD, et al. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. *Am J Epidemiol* 1996; 143:1195–1202.
- Zucchetto A, Serraino D, Polesel J, et al. Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. *Eur J Cancer Prev* 2009;18:316–321.
- Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* 2010;127:442–451.
- Saltzman BS, Doherty JA, Hill DA, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. *Am J Epidemiol* 2008;167:607–614.
- Weiderpass E, Persson I, Adami HO, et al. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). *Cancer Causes Control* 2000;11:185–192.
- Friedenreich CM, Biel RK, Lau DC, et al. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. *Cancer Epidemiol Biomarkers Prev* 2011;20:2384–2395.
- Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2005;365:1543–1551.
- Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. *New Engl J Med* 1980;302:551–554.
- Allen NE, Tsilidis KK, Key TJ, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition. *Am J Epidemiol* 2010;172:1394–1403.
- Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. *Menopause* 2010;17:642–653.
- Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. *J Natl Cancer Inst* 2001;93:684–690.
- Fisher B, Costantino J, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 2005;97:1652–1662.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet* 2011;378:771–784.
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst* 1998;90:1371–1388.
- DeMichele A, Troxel AB, Berlin JA, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. *J Clin Oncol* 2008;26:4151–4159.
- Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. *J Natl Cancer Inst* 2005;97:375–384.
- Davies C, Pan H, Godwin J, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* 2013;381:805–816.
- Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA* 2011;305:2304–2310.
- Broadus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. *Cancer* 2006;106:87–94.
- Meyer LA, Broadus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. *Cancer Control* 2009;16:14–22.
- Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. *J Clin Oncol* 2008;26:5965–5971.
- Burbos N, Musonda P, Duncan TJ, et al. Estimating the risk of endometrial cancer in symptomatic postmenopausal women: a novel clinical prediction model based on patients' characteristics. *Int J Gynecol Cancer* 2011;21: 500–506.
- Dijkhuizen F, Mol B, Brolmann H, et al. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. *Cancer* 2000;89:1765–1772.
- Bell DJ, Pannu HK. Radiological assessment of gynecologic malignancies. *Obstet Gynecol Clin North Am* 2011;38:45–68.
- Goldstein RB, Bree RL, Benson CB, et al. Evaluation of the women with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. *J Ultrasound Med* 2001;20:1025–1036.
- Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. *JAMA* 1998;280:1510–1517.
- Timmermans A, Opmeer BC, Khan KS, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. *Obstet Gynecol* 2010;116: 160–167.
- Bansal N, Herzog TJ, Brunner-Brown A, et al. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. *Gynecol Oncol* 2008;111:208–212.
- Frei KA, Kinkel K, Bonel HM, et al. Prediction of deep myometrial invasion in patients with endometrial cancer: clinical utility of contrast-enhanced MR imaging—a meta-analysis and Bayesian analysis. *Radiology* 2000;216:444–449.
- Kitajima K, Murakami K, Kaji Y, et al. Established, emerging and future applications of FDG-PET/CT in the uterine cancer. *Clin Radiol* 2011;66: 297–307.
- Sood AK, Buller RE, Burger RA, et al. Value of preoperative CA125 level in the management of uterine cancer and prediction of clinical outcome. *Obstet Gynecol* 1997;90:441–447.
- Todo Y, Sakuragi N, Nishida R, et al. Combined use of magnetic resonance imaging, CA125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. *Am J Obstet Gynecol* 2003;188:1265–1272.
- Patsner B, Tenhoppin DJ, Mann WJ. Use of serum CA125 levels to monitor therapy of patients with advanced or recurrent endometrial carcinoma. *Eur J Gynecol Oncol* 1989;10:322–325.
- Silverberg SG, Mutter GL, Kurman RJ, et al. Tumors of the uterine corpus: epithelial tumors and related lesions. In: Tavassoli FA, Stratton MR, eds. *WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs*. Lyon, France: IARC Press; 2003:221–232.
- Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. *Cancer* 1985;56:403–412.
- Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. *Cancer* 2006;106:812–819.
- Leitao MM Jr, Chi DS. Fertility-sparing options for patients with gynecologic malignancies. *Oncologist* 2005;10:613–622.
- Cirisano FD Jr, Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. *Gynecol Oncol* 1999;74:385–394.
- Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. *Mod Pathol* 2010;23:781–789.
- Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. *Cancer* 1987;60:2035–2041.
- Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathologic risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. *Gynecol Oncol* 1991;40:55–65.
- Abu-Rustum NR, Zhou Q, Gomez JD, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. *Gynecol Oncol* 2010; 116:399–403.
- Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcome of the randomized PORTEC-1 Trial for endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 2011;81:631–638.
- Alekhtiar KM, Venkatraman E, Abu-Rustum N, et al. Is endometrial carcinoma intrinsically more aggressive in elderly patients? *Cancer* 2003;98:2368–2377.
- Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. *Int J Gynaecol Obstet* 2006;95:S105–S143.
- Mariani A, Dowdy SC, Keeney GL, et al. Predictors of vaginal relapse in stage I endometrial cancer. *Gynecol Oncol* 2005;97:820–827.
- Rittenberg PVC, Lotocki RJ, Heywood MS, et al. Stage II endometrial carcinoma: limiting post-operative radiotherapy to the vaginal vault in node-negative tumors. *Gynecol Oncol* 2005;98:434–438.
- Guntupalli SR, Zigelboim I, Kizer NT, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. *Gynecol Oncol* 2012;124:31–35.
- Bokhman JV. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol* 1983;15:10–17.
- Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. *Nat Rev Clin Oncol* 2011;8:261–271.
- Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013;497:67–73.
- Pecorelli S. International Federation of Gynecology and Obstetrics: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynecol Obstet* 2009;105:103–104.

55. Page BR, Pappas L, Cooke EW, et al. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? Revised staging, endometrial cancer, histology. *Int J Gynecol Cancer* 2012;22:593–598.
56. Abu-Rustum NR, Zhou Q, Iasonos A, et al. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? *Int J Gynecol Cancer* 2011;21:511–516.
57. Milgrom SA, Kollmeier MA, Abu-Rustum NR, et al. Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer. *Gynecol Oncol* 2013;130:49–53.
58. Alhilli MM, Dowdy SC, Weaver AL, et al. Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study. *Gynecol Oncol* 2012;125:109–113.
59. Ramus SJ, Elmasry K, Luo Z, et al. Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. *Clin Cancer Res* 2008;14:5840–5848.
60. Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group study LAP2. *J Clin Oncol* 2009;27:5331–5336.
61. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging uterine cancer: Gynecologic Oncology Group LAP2 study. *J Clin Oncol* 2012;30:695–700.
62. Gala RB, Margulies R, Steinberg A, et al. Systematic review of robotic surgery in gynecology: robotic techniques compared with laparoscopy and laparotomy. *J Minim Invasive Gynecol* 2014;21:353–361.
63. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. *J Natl Cancer Inst* 2008;100:1707–1716.
64. ASTEC study group, Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. *Lancet* 2009;373:125–136.
65. Ballester M, Dubernard G, Lécuru F, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). *Lancet Oncol* 2011;12:469–476.
66. Abu-Rustum NR. The increasing credibility of sentinel lymph node mapping in endometrial cancer. *Ann Surg Oncol* 2013;20:353–354.
67. Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. *Gynecol Oncol* 2012;125:531–535.
68. Abu-Rustum NR, Gomez JD, Alekhtiar KM, et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. *Gynecol Oncol* 2009;115:236–238.
69. Barlin JN, Zhou Q, St Clair CM, et al. Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. *Gynecol Oncol* 2013;130:452–456.
70. Sorbe B, Nordström B, Mäenpää J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. *Int J Gynecol Cancer* 2009;19:873–878.
71. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-I endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. *Post Operative Radiation Therapy in Endometrial Carcinoma*. *Lancet* 2000;355:1404–1411.
72. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. *J Clin Oncol* 2004;22:1234–1241.
73. Horowitz NS, Peters WA 3rd, Smith MR, et al. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. *Obstet Gynecol* 2002;99:235–240.
74. Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IC3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. *Gynecol Oncol* 2001;82:371–374.
75. Nout RA, Smit VT, Putter H, et al. PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. *Lancet* 2010;375:816–823.
76. Sorbe B, Horvath G, Andersson H, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma—a prospective randomized study. *Int J Radiat Oncol Biol Phys* 2012;82:1249–1255.
77. Ng TY, Perrin LC, Nicklin JL, et al. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy. *Gynecol Oncol* 2000;79:490–494.
78. Solhjem MC, Petersen IA, Haddock MG. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. *Int J Radiat Oncol Biol Phys* 2005;62:1379–1384.
79. Long KC, Zhou Q, Hensley ML, et al. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer. *Gynecol Oncol* 2012;125:99–102.
80. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2004;92:744–751.
81. Ng TY, Nicklin JL, Perrin LC, et al. Postoperative vaginal vault brachytherapy for node-negative Stage II (occult) endometrial carcinoma. *Gynecol Oncol* 2001;81:193–195.
82. Cannon GM, Geyer H, Terakedis BE, et al. Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma. *Gynecol Oncol* 2009;113:176–180.
83. Onsrud M, Cvancarova M, Hellebust TP, et al. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. *J Clin Oncol* 2013;31:3951–3956.
84. Kiess AP, Damast S, Makker V, et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. *Gynecol Oncol* 2012;127:321–325.
85. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. *Gynecol Oncol* 2008;108:226–233.
86. Maggi R, Lissani A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. *Br J Cancer* 2005;266–271.
87. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 2006;24:36–44.
88. Kuoppala T, Mäenpää J, Tomas E, et al. Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. *Gynecol Oncol* 2008;110:190–195.
89. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. *Eur J Cancer* 2010;46:2422–2431.
90. Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. *Gynecol Oncol* 2006;103:155–159.
91. Milgrom SA, Kollmeier MA, Abu-Rustum NR, et al. Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. *Int J Radiat Oncol Biol Phys* 2013;87:S128.
92. Milgrom SA, Kollmeier MA, Abu-Rustum NR, et al. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer. *Gynecol Oncol* 2013;130:436–440.
93. Shih KK, Milgrom SA, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. *Gynecol Oncol* 2013;128:535–539.
94. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. *N Engl J Med* 1961;264:216–222.
95. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. *J Clin Oncol* 1999;17:1736–1744.
96. Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 1996;14:357–361.
97. McMeeke DS, Gordon A, Fowler J, et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. *Gynecol Oncol* 2003;90:64–69.
98. Covens AL, Filiaci V, Gersell D, et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2011;120:185–188.
99. Emons G, Gunthert A, Thiel FC, et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie. *Gynecol Oncol* 2013;129:495–499.
100. Kokka F, Brockbank E, Oram D, et al. Hormonal therapy in advanced or recurrent endometrial cancer. *Cochrane Database Syst Rev* 2010;12:CD007926.
101. Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. *Gynecol Oncol* 2007;106:325–333.
102. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2004;92:10–14.
103. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2004;92:4–9.
104. Pandya KJ, Yeap BY, Weiner LM, et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group study (E4882). *Am J Clin Oncol* 2001;24:43–46.
105. Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2000;78:212–216.
106. Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers—a study of the National Cancer Institute of Canada Clinical Trials Group. *Int J Gynecol Cancer* 2004;14:650–658.
107. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 2001;19:364–367.

108. Covens A, Thomas G, Shaw P, et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. *Gynecol Oncol* 1997;64:126–129.
109. Lhomme C, Vennin P, Callet N, et al. A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. *Gynecol Oncol* 1999;75:187–193.
110. Asbury RF, Brunetto VL, Lee RB, et al. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Am J Clin Oncol* 2002;25:557–560.
111. Oza AM OA, Clamp AR, Pignata S, et al. A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma. *J Clin Oncol* 2011;29:abstract #5009.
112. Gu C, Zhang Z, Yu Y, et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. *Cancer Sci* 2011;102:557–564.
113. Fleming GF FV, Hanjani P, Burke JJ, et al. Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248. *J Clin Oncol* 2011;29:abstr #5014.
114. Slomovitz BM BJ, Johnston TA, Mura D, et al. A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. *J Clin Oncol* 2011;29:abstr #5012.
115. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 1994;12:1408–1414.
116. Pawinski A, Tumolo S, Hoessel G, et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. *Eur J Obstet Gynecol Reprod Biol* 1999;86:179–183.
117. Aapro MS, van Wijk FH, Bolis G, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. *Ann Oncol* 2003;14:441–448.
118. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. *Ann Oncol* 2004;15:1173–1178.
119. Thigpen JT, Blessing JA, Homesley H, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. *Gynecol Oncol* 1989;33:68–70.
120. Burke TW, Munkarah A, Kavanagh JJ, et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. *Gynecol Oncol* 1993;51:397–400.
121. van Wijk FH, Lhomme C, Bolis G, et al. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. *Eur J Cancer* 2003;39:78–85.
122. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 2004;22:3902–3908.
123. Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2003;88:277–281.
124. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. *J Clin Oncol* 2004;22:2159–2166.
125. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. *Gynecol Oncol* 2009;112:543–552.
126. Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2012;125:771.
127. Homesley HD, Blessing JA, Sorosky J, et al. Phase II trial of liposomal doxorubicin at 40 mg/m² every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2005;98:294–298.
128. Muggia FM, Blessing JA, Sorosky J, et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2002;20:2360–2364.
129. Pignata S, Scambia G, Pisano C, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. *Br J Cancer* 2007;96:1639–1643.
130. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. *J Clin Oncol* 2011;29:3628–3635.
131. Nagao S, Nishio S, Michimae H, et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study. *Gynecol Oncol* 2013;131:567–573.
132. Thigpen JT, Blessing JA, Lagasse LD, et al. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. *Am J Clin Oncol* 1984;7:253–256.
133. Rose PG, Blessing JA, Lewandowski GS, et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 1996;63:101–104.
134. Sutton GP, Blessing JA, Homesley HD, et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. *Cancer* 1994;73:1453–1455.
135. Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P. *J Clin Oncol* 2009;27:3104–3108.
136. Fracasso PM, Blessing JA, Molpus KL, et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2006;103:523–526.
137. Tait DL, Blessing JA, Hoffman JS, et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2011;121:118–121.
138. Escobar PF, Markman M, Zanotti K, et al. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. *J Cancer Res Clin Oncol* 2003;129:651–654.
139. Di Legge A, Trivellizzi IN, Moruzzi MC, et al. Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer. *Int J Gynecol Cancer* 2011;21:1446–1451.
140. Miller DS, Blessing JA, Lentz SS, et al. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2002;87:247–251.
141. Katsumata N, Noda K, Nozawa S, et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study. *Br J Cancer* 2005;93:999–1004.
142. Miller DS, Blessing JA, Drake RD, et al. A phase II evaluation of pemetrexed (Aimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. *Gynecol Oncol* 2009;115:443–446.
143. Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 2012;127:538–543.
144. Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. *Gynecol Oncol* 2010;117:37–40.
145. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. *J Clin Oncol* 2011;29:3278–3285.
146. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. *Cancer* 2010;116:5415–5419.
147. Ray-Coquard I, Favier L, Weber B, et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. *Br J Cancer* 2013;108:1771–1777.
148. Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. *Br J Cancer* 2013;108:1021–1026.
149. Mackay HJ, Eisenhauer EA, Kamel-Reid S, et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. *Cancer* 2014;120:603–610.
150. Miller DS, Blessing JA, Lentz SS, et al. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2002;87:247–251.
151. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. *Gynecol Oncol* 2007;106:16–22.
152. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. *J Clin Oncol* 2011;29:2259–2265.
153. Correa R MH, Hirte HW, Morgan R, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. *J Clin Oncol* 2010;18:abstr #5038.
154. Myers AP. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway—the devil is in the details. *Clin Cancer Res* 2013;19:5264–5274.
155. Myers AP, Broaddus R, Makker V, et al. Phase II, two-stage, two-arm, PI3KCA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). *J Clin Oncol* 2013;31:abstr #5524.
156. Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2013;129:22–27.
157. Einstein MH WR, Morgan R, Cristea MC, et al. Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer. *J Clin Oncol* 2012;30:3332.
158. Gadducci A, Tana R, Cosio S, et al. Molecular target therapies in endometrial cancer: from the basic research to the clinic. *Gynecol Endocrinol* 2008;24:239–249.
159. Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 2013;129:486–494.

160. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. *J Clin Oncol* 2008;26:4319–4325.
161. Slomovitz B SK, Miller D. Phase II study of cetuximab (Erbix) in patients with progressive or recurrent endometrial cancer. *Gynecol Oncol* 2010;116:abstr.
162. Leslie KK, Sill MW, Lankes HA, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. *Gynecol Oncol* 2012;127:345–350.
163. Villella JA, Cohen S, Smith DH, et al. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. *Int J Gynecol Cancer* 2006;16:1897–1902.
164. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2010;116:15–20.
165. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell* 2004;6:117–127.
166. Volker P, Grundker C, Schmidt O, et al. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. *Am J Obstet Gynecol* 2002;186:171–179.
167. Engel J, Emons G, Pinski J, et al. AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. *Expert Opin Investig Drugs* 2012;21:891–899.
168. Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. *Proc Natl Acad Sci U S A* 2008;105:8713–8717.
169. Konecny GE, Kolarova T, O'Brien NA, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BCJ398 in human endometrial cancer cells. *Mol Cancer Ther* 2013;12:632–642.
170. Bradford LS, Rauh-Hain JA, Schorge J, et al. Advances in the management of recurrent endometrial cancer. *Am J Clin Oncol* 2013 (epub ahead of print).
171. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. *Sci Transl Med* 2010;2:53ra75.
172. Forster MD, Dedes KJ, Sandhu S, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. *Nat Rev Clin Oncol* 2011;8:302–306.
173. Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival. *Gynecol Oncol* 2014;132:236–240.
174. Ko EM, Walter P, Jackson A, et al. Metformin is associated with improved survival in endometrial cancer. *Gynecol Oncol* 2014;132:438–442.
175. Iglesias DA, Yates MS, van der Hoeven D, et al. Another surprise from metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. *Mol Cancer Ther* 2013;12:2847–2856.
176. Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. *Gynecol Oncol* 2003;89:201–209.
177. Bristow RE, Santillan A, Zahurak ML, et al. Salvage cytoreductive surgery for recurrent endometrial cancer. *Gynecol Oncol* 2006;103:281–287.
178. Awtrey CS, Cadungog MG, Leitao MM, et al. Surgical resection of recurrent endometrial carcinoma. *Gynecol Oncol* 2006;102:480–488.
179. Berek JS, Howe C, Lagasse LD, et al. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. *Gynecol Oncol* 2005;99:153–159.
180. Shepherd JH, Ngan HY, Neven P, et al. Multivariate analysis of factors affecting survival in pelvic exenteration. *Int J Gynecol Cancer* 1994;4:361–370.
181. Barakat RR, Goldman NA, Patel DA, et al. Pelvic exenteration for recurrent endometrial cancer. *Gynecol Oncol* 1999;75:99–102.
182. Nag S, Yacoub S, Copeland LJ, et al. Interstitial brachytherapy for salvage treatment of vaginal recurrences in previously unirradiated endometrial cancer patients. *Int J Radiat Oncol Biol Phys* 2002;54:1153–1159.
183. Pai HH, Souhami L, Clark BG, et al. Isolated vaginal recurrences in endometrial carcinoma: treatment results using high-dose-rate intracavitary brachytherapy and external beam radiotherapy. *Gynecol Oncol* 1997;66:300–307.
184. Hart KB, Han I, Shamsa F, et al. Radiation therapy for endometrial cancer in patients treated for postoperative recurrence. *Int J Radiat Oncol Biol Phys* 1998;41:7–11.
185. Wylie J, Irwin C, Pintilie M, et al. Results of radical radiotherapy for recurrent endometrial cancer. *Gynecol Oncol* 2000;77:66–72.
186. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. *Int J Radiat Oncol Biol Phys* 2003;56:1366–1372.
187. Lin LL, Grigsby PW, Powell MA, et al. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. *Int J Radiat Oncol Biol Phys* 2005;63:500–504.
188. Petignat P, Jolicœur M, Alabdai A, et al. Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. *Gynecol Oncol* 2006;101:445–449.
189. Viswanathan AN, Lee H, Berkowitz R, et al. A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. *Gynecol Oncol* 2014;132:55–60.
190. D'Angelo E, Prat J. Uterine sarcomas, a review. *Gynecol Oncol* 2010;116:2:131–139.
191. Saglam O, Husain S, Toruner G. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma. *Int J Gynecol Pathol* 2013;32:493–500.
192. Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. *Gynecol Oncol* 2004;93:204–208.
193. Curtis RE, Freedman DM, Sherman ME, et al. Risk of malignant mixed müllerian tumors after tamoxifen therapy for breast cancer. *J Natl Cancer Inst* 2004;96:70–74.
194. Vaccarello L, Curtin JP. Presentation and management of carcinosarcoma of the uterus. *Oncology (Williston Park)* 1992;6:45–49; discussion 53–54, 59.
195. McCluggage WC. Uterine carcinosarcomas (malignant mixed müllerian tumors) are metaplastic carcinomas. *Int J Gynecol Cancer* 2002;12:687–690.
196. Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. *Am J Surg Pathol* 1995;19:666–674.
197. Aghajanian C, Sill MW, Secord AA, et al. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. *Gynecol Oncol* 2012;126:424–427.
198. Sutton G. Uterine sarcomas 2013. *Gynecol Oncol* 2013;130:3–5.
199. Temkin SM, Hellmann M, Lee YC, et al. Early-stage carcinosarcoma of the uterus: the significance of lymph node count. *Int J Gynecol Cancer* 2007;17:215–219.
200. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. *Int J Gynecol Pathol* 1990;9:1–19.
201. Vaidya AP, Horowitz NS, Oliva E, et al. Uterine malignant mixed müllerian tumors should not be included in studies of endometrial carcinoma. *Gynecol Oncol* 2006;103:684–687.
202. Reed NS, Mangioni C, Malstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). *Eur J Cancer* 2008;44:808–818.
203. Gonzalez Bosquet J, Terstriepe SA, Cliby WA, et al. The impact of multimodal therapy on survival for uterine carcinosarcomas. *Gynecol Oncol* 2010;116:419–423.
204. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. *J Clin Oncol* 1985;3:1240–1245.
205. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-irifosamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. *Gynecol Oncol* 2007;107:177–185.
206. Desai NB, Kollmeier MA, Makker V, et al. Early-stage carcinosarcoma treated with adjuvant radiotherapy and chemotherapy. *Oncology* 2014 (abstract).
207. National Comprehensive Cancer Network. *NCCN Guidelines & Clinical Resources: Uterine Neoplasms*. Version 1.2014. Fort Washington, PA: National Comprehensive Cancer Network.
208. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. *Cancer* 1983;52:626–632.
209. Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). *Cancer* 1985;55:1648–1653.
210. Thigpen JT, Blessing JA, Beecham J, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. *J Clin Oncol* 1991;9:1962–1966.
211. Sutton GP, Blessing JA, Rosenshein N, et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). *Am J Obstet Gynecol* 1989;161:309–312.
212. van Rijswijk RE, Vermorken JB, Reed N, et al. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). *Eur J Cancer* 2003;39:481–487.
213. Sutton G, Brunetto VL, Kilgore L, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol* 2000;79:147–153.
214. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:526–531.
215. Powell MA, Filiaci VL, Rose PG, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. *J Clin Oncol* 2010;28:2727–2731.
216. Quade BJ, Wang TY, Somberger K, et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. *Genes Chromosomes Cancer* 2004;40:97–108.
217. Leibsohn S, d'Ablaing G, Mishell DR Jr, et al. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. *Am J Obstet Gynecol* 1990;162:968–974; discussion 974–976.
218. Leitao MM, Sonoda Y, Brennan MF, et al. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. *Gynecol Oncol* 2003;91:209–212.

219. Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. *Histopathology* 2009;54:355–364.
220. Iasonos A, Keung EZ, Zivanovic O, et al. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. *Cancer* 2013;119:1816–1822.
221. Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. *Ann Oncol* 2013;24:1099–1104.
222. Hensley ML, Wathen JK, Maki RG, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). *Cancer* 2013;119:1555–1561.
223. Slayton RE, Blessing JA, DiSaia PJ, et al. Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. *Cancer Treat Rep* 1987;71:661–662.
224. Thigpen JT, Blessing JA, Orr JW Jr, et al. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study. *Cancer Treat Rep* 1986;70:271–274.
225. Gershenson DM, Kavanagh JJ, Copeland LJ, et al. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. *J Clin Oncol* 1987; 5:618–621.
226. Sutton GP, Blessing JA, Homesley HD, et al. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. *Gynecol Oncol* 1994;53:24–26.
227. Curtin JP, Blessing JA, Soper JT, et al. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. *Gynecol Oncol* 2001;83:268–270.
228. Miller BE, Blessing JA, Stehman FB, et al. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol* 2010;118:139–144.
229. Miller DS, Blessing JA, Schilder J, et al. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol* 2005;98:217–221.
230. Mackay HJ, Buckanovich RJ, Hirte H, et al. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. *Gynecol Oncol* 2012;125:136–140.
231. Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. *Gynecol Oncol* 2010;117:37–40.
232. Sutton G, Blessing J, Hanjani P, et al. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol* 2005;96:749–752.
233. Miller DS, Blessing JA, Kilgore LC, et al. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group study. *Am J Clin Oncol* 2000;23:355–357.
234. Thigpen T, Blessing JA, Yordan E, et al. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol* 1996;63:120–122.
235. Monk BJ, Blessing JA, Street DC, et al. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a Gynecologic Oncology Group study. *Gynecol Oncol* 2012;124:48–52.
236. Sutton GP, Blessing JA, Barrett RJ, et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. *Am J Obstet Gynecol* 1992;166:556–559.
237. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. *Gynecol Oncol* 1996;62:226–229.
238. Hensley ML, Blessing JA, Mannel R, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. *Gynecol Oncol* 2008;109:329–334.
239. Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, et al. Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel. *Invest New Drugs* 2007;25:279–281.
240. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). *J Clin Oncol* 2009;27:3126–3132.
241. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2012;379:1879–1886.
242. Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. *Cancer* 2004;101:1455–1462.
243. O'Ceirbhail R, Zhou Q, Iasonos A, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. *Gynecol Oncol* 2010;116: 424–429.
244. George S, Feng Y, Manola J, et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. *Cancer* 2014;120:738–743.
245. Rose PG, Blessing JA, Soper JT, et al. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. *Gynecol Oncol* 1998;70:267–271.
246. Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. *Cancer* 2005;104:1706–1712.
247. Gallup DG, Blessing JA, Andersen W, et al. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. *Gynecol Oncol* 2003;89:48–51.
248. Look KY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. *Gynecol Oncol* 2004;92:644–647.
249. Hensley ML, Sill MW, Scribner DR Jr, et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. *Gynecol Oncol* 2009;115:460–465.
250. Chan JK, Kavar NM, Shin JY, et al. Endometrial stromal sarcoma: a population-based analysis. *Br J Cancer* 2008;99:1210–1215.
251. Rauh-Hain JA, del Carmen MG. Endometrial stromal sarcoma: a systematic review. *Obstet Gynecol* 2013;122:676–683.
252. Yoon A, Park JY, Lee YY, et al. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: A multicenter review of 114 cases. *Gynecol Oncol* 2014;132:70–75.
253. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956–1992: incidence, survival and mortality. *Eur J Cancer* 1997;33:907–911.
254. Sampath S, Schultheiss TE, Ryu JK, et al. The role of adjuvant radiation in uterine sarcomas. *Int J Radiat Oncol Biol Phys* 2010;76:728–734.
255. Tanner EJ, Garg K, Leitao MM Jr, et al. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. *Gynecol Oncol* 2012;127:27–31.